Rigor Reviewed

Rigor-Reviewed Manuscript

Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo.

Name: Αlpha¹ Rigor Record — Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo.
Item: Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo.
Rating: 96
Author: Αlpha¹

PALM007 Writing Group, Ali R, Alonga J, Biampata JL, Kombozi Basika M, Maljkovic Berry I, Bisento N, Blum E, Bonnett T, Cone K, Crozier I, Davey R, Dilu A, Dodd LE, Gulati I, Hruby D, Ibanda A, Isse F, Kasareka SS, Kayembe G, Kojan R, Luzolo EK, Lane HC, Lawanga L, Liesenborghs L, Shosongo Lunghe C, Lula Y, Lusakibanza M, Lutete GT, Mbala-Kingebeni P, Miranda A, Mukadi-Bamuleka D, Mukendi G, Lupola PM, Muyembe-Tamfum JJ, Ndungunu R, Nganga B, Ntamabyaliro N, Nussenblatt V, Omulepu I, Omalokoho Onosomba J, Proschan M, Rubenstein K, Saknite I, Schechner A, Shaw-Saliba K, Sivahera B, Smolskis M, Tillman A, Tkaczyk E, Tshimanga C, Tshiani Mbaya O, Tshomba A, Yemba Unda Tshomba F, Vallee D, Vogel S, Weyers S

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3.25★ (Adequate), 0 critical, 2 high issues for “Tecovirimat for Clade I MPXV Infection in the Democratic Republic of Congo.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 7 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.
No data or code availability links were detected to verify.

Problems surfaced3 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously designed and reported double-blind randomized placebo-controlled trial of tecovirimat for mpox. The main methodological strength is the robust trial design with pre-specified endpoints, power analysis, and transparent reporting. The primary weakness is the vague data availability statement, which lacks a clear mechanism for accessing de-identified patient data.

Both reviewers independently scored all eight dimensions and agreed on every status; no divergence required reconciliation. The study is an interventional clinical trial; animal-related criteria (IACUC, housing, species/strain) are not applicable. The statistics verification recomputed only 3 reported tests consistently; the remainder of the statistical analysis is unverified and should not be assumed correct.

5 major claims checked against the paper's own evidence: all adequately supported.

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks.

3 integrity concerns flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior work on tecovirimat's mechanism (inhibition of viral envelopment), activity in non-human primate models, and safety in healthy volunteers. It also acknowledges the lack of randomized controlled trial evidence in mpox patients, which directly motivates the trial. The rationale linking the premise to the study objectives is explicit, and the paper addresses the gap in prior research by conducting a randomized trial.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise, citing prior research on tecovirimat's mechanism, animal efficacy, and safety, and logically motivates the trial.

Evidence

paraphrase[Introduction, paragraph 2]

“Tecovirimat prevents release of viral particles from infected cells by inhibiting viral envelopment during final stages of viral maturation.”

direct quote[Introduction, paragraph 1]

“Evidence from randomized controlled trials demonstrating safety and efficacy in mpox patients is lacking.”